These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26950724)

  • 1. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
    Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
    Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
    Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
    Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
    Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
    Alhamad T; Venkatachalam K; Daloul R; Brennan DC; Malone AF
    Transplantation; 2017 Aug; 101(8):e287-e288. PubMed ID: 28422926
    [No Abstract]   [Full Text] [Related]  

  • 9. Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.
    Shuker N; Bouamar R; Hesselink DA; van Gelder T; Caliskan K; Manintveld OC; Balk AH; Constantinescu AA
    Exp Clin Transplant; 2018 Jun; 16(3):326-332. PubMed ID: 28969528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
    O'Regan JA; Canney M; Connaughton DM; O'Kelly P; Williams Y; Collier G; deFreitas DG; O'Seaghdha CM; Conlon PJ
    J Nephrol; 2016 Apr; 29(2):269-276. PubMed ID: 26374111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.
    Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ
    Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
    Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
    Soliman KM; Posadas Salas AC; Taber DJ
    Exp Clin Transplant; 2019 Dec; 17(6):707-713. PubMed ID: 30570456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
    Bentata Y
    Artif Organs; 2020 Feb; 44(2):140-152. PubMed ID: 31386765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.